[Correlation between serum adiponectin level and cognitive function in patients with Alzheimer's disease]
Wei Li1, Yi Tian, Yan-Yao Deng
11Department of Neurology, ThirdXiangya Hospital, Central South University, Changsha 410013, China; 2Neuromedical Center, First Hospital of Changsha, Changsha 410005, China.
Objective:
To investigate serum adiponectin level in patients with Alzheimer's disease (AD) and its correlation with the patients' cognitive function.
Methods:
This case-control study was conducted in 90 patients with a highly probable diagnosis ofAD, who were divided into mild, moderate and severe group saccording to the MMSE score. Ninety healthy subjects matched for age and gender with the AD patients were selected as the control group. The serum levels ofadiponectin in the participants were detected using enzyme-linked immunosorbent assay.
Results:
Serum adiponectin level was significantly lower in the AD group than in the control group (P<0.05). Of the 3 subgroups of the AD patients, the moderate and severe AD groups showed significantly lower serum adiponectin level sthan the control group (P<0.05), but the difference in adiponectin levels was not significant between the mild AD group and the control group (P>0.05); serum adiponectin levels also differed significantly among the 3 subgroups of AD patients (P<0.05). Serum adiponectin level was positively correlated with the MMSE score in the AD patients (r=0.683, P<0.001).
Conclusion:
Serum adiponectin levels are reduced in AD patients and associated with the degree of cognitive impairment.
More Related Videos
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
